Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC
Written by
Cancer Network
Published
0
comments
0
min
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.